Innovative Bispecific Nanobody Targeting ALB and TNF for Rheumatoid Arthritis Therapy
VHH-P633 is a next-generation bispecific nanobody construct in the biological testing stage, designed for the treatment of rheumatoid arthritis. This fusion protein targets two key molecules: albumin (ALB) and tumor necrosis factor (TNF). By harnessing the specificities of camelid-derived variable heavy chain domains, VHH-P633 offers a novel approach with high potential against rheumatoid arthritis. The dual targeting of ALB and TNF combines the benefits of enhanced pharmacokinetics with targeted immunomodulation, reflecting a promising advancement beyond traditional monoclonal antibody therapies.
| Candidate | VHH-P633 |
| Target | albumin (ALB) tumor necrosis factor (TNF) |
| Modality | humanized bispecific VHH |
| Indication | Rheumatoid Arthritis |
Licensing Opportunity
VHH-P633 is currently available for out-licensing opportunities. We welcome inquiries from industry partners interested in collaborative development, commercialization, or co-development in the field of autoimmune therapeutics.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P633 |
Modality
VHH-P633 is a bispecific nanobody fusion construct that integrates two single-domain antibodies: one directed against TNF and a second against ALB, joined by a flexible peptide linker. Expressed in E. coli Rosetta cells, this modular design exploits the unique structural properties of nanobodies, including small molecular size, high stability, and robust tissue penetration. By combining these attributes, VHH-P633 is well-suited for targeting inflamed tissues in rheumatoid arthritis. Its structure facilitates deep penetration into synovial tissue, sustained action via ALB binding, and superior manufacturability, offering a significant advantage over conventional antibody therapeutics.
Target
ALB and TNF are well-validated molecular targets in rheumatoid arthritis. ALB is the most abundant plasma protein, primarily produced by the liver and distributed in the bloodstream, playing roles in maintaining plasma oncotic pressure and drug pharmacokinetics. TNF is a pro-inflammatory cytokine mainly secreted by immune cells such as macrophages and T cells. Overexpression of TNF is a central driver of chronic joint inflammation in rheumatoid arthritis. Targeting ALB allows for improved serum half-life and tissue biodistribution, while targeting TNF directly modulates key inflammatory pathways. The simultaneous targeting of ALB and TNF positions VHH-P633 as a strategically differentiated therapy with potential for durable disease control in rheumatoid arthritis.
Mechanism of Action
VHH-P633 exerts its effect through high-affinity binding to both ALB and TNF. The anti-TNF component neutralizes pro-inflammatory TNF signaling, reducing cytokine-mediated joint inflammation and immune cell activation. The anti-ALB moiety binds circulating ALB, leveraging natural recycling mechanisms to extend systemic exposure and enhance pharmacokinetics. This dual mechanism not only suppresses established inflammatory pathways but also prolongs therapeutic presence in circulation. The nanobody platform also supports modular engineering for the development of multi-specific formats, antibody-drug conjugates, or further bispecific therapeutics targeting related pathways in autoimmune conditions.
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, systemic autoimmune disorder characterized by persistent joint inflammation, synovial proliferation, and progressive destruction of cartilage and bone. Affecting millions worldwide, this disease leads to significant disability and reduced quality of life. Standard therapies include conventional disease-modifying antirheumatic drugs, biologic agents targeting cytokines or immune cell surface markers, and small molecule inhibitors. Despite these options, many patients experience incomplete response, treatment intolerance, or relapse, highlighting substantial unmet clinical needs. Limitations of current therapies include suboptimal efficacy, immunogenicity, and the need for frequent dosing. The unique bispecific design of VHH-P633, targeting both ALB for prolonged half-life and TNF for direct immunomodulation, addresses these gaps by offering the potential for enhanced efficacy, improved safety, and greater patient convenience in the management of rheumatoid arthritis.